Epocrates Goes Negative
Epocrates (NAS: EPOC) reported earnings on Oct. 31. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Sep. 30 (Q3), Epocrates met expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue dropped slightly and GAAP earnings per share dropped to a loss.
Gross margins shrank, operating margins expanded, net margins dropped.
Epocrates notched revenue of $26.0 million. The four analysts polled by S&P Capital IQ predicted revenue of $26.0 million on the same basis. GAAP reported sales were 2.2% lower than the prior-year quarter's $26.6 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.02. The four earnings estimates compiled by S&P Capital IQ forecast $0.01 per share. GAAP EPS were -$0.02 for Q3 against $0.03 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 58.5%, 70 basis points worse than the prior-year quarter. Operating margin was -4.3%, 80 basis points better than the prior-year quarter. Net margin was -2.3%, 490 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $29.4 million. On the bottom line, the average EPS estimate is $0.04.
Next year's average estimate for revenue is $109.7 million. The average EPS estimate is $0.18.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 34 members out of 37 rating the stock outperform, and three members rating it underperform. Among eight CAPS All-Star picks (recommendations by the highest-ranked CAPS members), eight give Epocrates a green thumbs-up, and give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Epocrates is outperform, with an average price target of $11.00.
- Add Epocrates to My Watchlist.
The article Epocrates Goes Negative originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.